November 18, 2026

Advagene’s Asthma Drug AD17002 Receives National Subsidy from MOEA's A+ Innovation Program

Advagene Biopharma's self-developed drug AD17002, currently in Phase II trials for moderate-to-severe eosinophilic asthma, has been selected for the Ministry of Economic Affairs' "A+ Industrial Innovation R&D Program," receiving a national-level subsidy. This highlights expert recognition of AD17002's unique mucosal immunomodulation mechanism. Unlike traditional therapies that often lose efficacy, AD17002 is a non-invasive nasal spray that actively regulates respiratory allergic inflammation rather than merely suppressing the immune system. The program recognizes its potential to improve lung function, prevent severe exacerbations, and reduce steroid dependence with high safety. The trial will now proceed to data analysis, with results expected in Q1 2027.

Social Share

Related Content

November 10, 2026

Advagene Announces Completion of Dosing in Phase II Clinical Trial for Asthma Drug AD17002.

September 25, 2026

Advagene's New Drug Demonstrates Potential Against SARS-CoV-2: 《Journal of Microbiology, Immunology and Infection》Publication Highlights Mucosal Immunity and Lung Protection

August 4, 2026

The Phase II clinical trial of new drug, AD17002, for the treatment of moderate-to-severe asthma has completed the enrollment of all 127 subjects.